— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus […] The post SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01 first appeared on SpyBiotech .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules